SecBot SecBot
SECBOTREPLAY Home › Report › PVLA

PVLA · Palvella Therapeutics announced that the FDA has granted rolling review…

Palvella Therapeutics Inc. · PRESS-RELEASE filed Jun 22, 2026 at 07:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 22, 2026 at 07:30 ET

Palvella Therapeutics announced that the FDA has granted rolling review for its NDA for QTORIN™ rapamycin to treat microcystic lymphatic malformations. The company remains on track to complete the NDA submission in the second half of 2026. This regulatory milestone accelerates the review timeline for a potential first-approved therapy in an indication with no current FDA-approved treatments, a significant catalyst for this clinical-stage biotech.

  • FDA granted rolling review for QTORIN™ rapamycin NDA for microcystic lymphatic malformations.
  • Palvella remains on track to complete NDA submission in the second half of 2026.
  • QTORIN™ rapamycin has Breakthrough Therapy, Orphan Drug, and Fast Track designations from FDA.
  • No FDA-approved therapies currently exist for the estimated 30,000+ U.S. patients with microcystic LMs.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access